Search research articles
Contact Us
Filters
Showing results (41-50 of 101) with videos related to
Page
of 11
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
December 21, 2004
A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway
C François, M Toumi, A-M Aakhus, et al.
The European Respiratory Journal
|
November 1, 1990
Manufacturer's information insert and subjective theophylline side-effects
D Vesco, M Toumi, F Faraj, et al.
Psychiatry Research
|
January 26, 2000
Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale
C Lançon, P Auquier, G Reine, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Social Contacts Reduce Negative Symptoms, Especially Emotional Withdrawal in Patients with Schizophrenia
A Millier, K Siegrist, I Amri, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Comparative Analysis of Hta Decisions, Price and Reimbursement Level of Orphan Drugs In France and Italy
D Korchagina, F Tavella, C Rémuzat, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Health Technology Assessment, Price and Reimbursement Review for Orphan Drugs In France
D Korchagina, C Rémuzat, J Rodrigues, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Clinical and Economic Outcomes of Memantine Used in Moderate or Severe Dementia Patients in China: Results from a Health Economic Model
L Ge, E Clay, J Yan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
A Comparison of Additional Benefit Scores in Germany (Gba) and France (Has)
I Soussi, M Thivolet, A Kornfeld, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
A Literature Review of Patient Advocacy Group (Pag) Involvement in HTA
N Hicks, N A Hawken, C Arvin-Berod, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Disease Management, Resource Utilisation and Associated Cost for Moderate and Severe Dementia Patients in China: Results from a Delphi Panel
J Yan, L Ge, E Clay, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 101) with videos related to
Sort By:
Page
of 11
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
December 21, 2004
A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway
C François, M Toumi, A-M Aakhus, et al.
The European Respiratory Journal
|
November 1, 1990
Manufacturer's information insert and subjective theophylline side-effects
D Vesco, M Toumi, F Faraj, et al.
Psychiatry Research
|
January 26, 2000
Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale
C Lançon, P Auquier, G Reine, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Social Contacts Reduce Negative Symptoms, Especially Emotional Withdrawal in Patients with Schizophrenia
A Millier, K Siegrist, I Amri, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Comparative Analysis of Hta Decisions, Price and Reimbursement Level of Orphan Drugs In France and Italy
D Korchagina, F Tavella, C Rémuzat, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Health Technology Assessment, Price and Reimbursement Review for Orphan Drugs In France
D Korchagina, C Rémuzat, J Rodrigues, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Clinical and Economic Outcomes of Memantine Used in Moderate or Severe Dementia Patients in China: Results from a Health Economic Model
L Ge, E Clay, J Yan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
A Comparison of Additional Benefit Scores in Germany (Gba) and France (Has)
I Soussi, M Thivolet, A Kornfeld, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
A Literature Review of Patient Advocacy Group (Pag) Involvement in HTA
N Hicks, N A Hawken, C Arvin-Berod, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Disease Management, Resource Utilisation and Associated Cost for Moderate and Severe Dementia Patients in China: Results from a Delphi Panel
J Yan, L Ge, E Clay, et al.
Page
of 11